UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I/IIa study in patients with recurrent IDH-mutant glioma will investigate the safety and preliminary efficacy of AZD9574 in combination with temozolomide.
Conditions
Glioma
Glioblastoma
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This non-therapeutic study aims to collect prospective neurocognitive and imaging data before, during, and after surgery.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
The goal of this phase I clinical trial is to demonstrate that a metabolic imaging technology can safely be used in patients with gliomas to help study treatment effects.
Conditions
Choroid Plexus Tumors
Pituitary Tumor
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Pineal Region Tumors
Glioma
Astrocytoma
Medulloblastoma
Oligodendroglioma
Glioblastoma
Ependymoma
Primary Objectives:
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This study will evaluate the feasibility and efficacy of various cognitive rehabilitation treatments in patients with grade II-III glioma.
Conditions
Glioma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy of safusidenib in newly diagnosed high-grade IDH-mutant astrocytoma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This is a phase 1 immunotherapy trial for patients with recurrent high-grade gliomas designed to evaluate the safety and biological activity of the gene therapy, SRN-101, administered prior to planned surgical resection.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant glioma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
This is a pilot study to develop a liquid biomarker of hypermutation in glioma patients previously treated with the chemotherapy temozolomide.